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Abstract: Feline leukemia virus (FeLV) is a retrovirus of cats worldwide. High viral loads are associated
with progressive infection and the death of the host, due to FeLV-associated disease. In contrast, low
viral loads, an effective immune response, and a better clinical outcome can be observed in cats with
regressive infection. We hypothesize that by lowering viral loads in progressively infected cats, using
CRISPR/SaCas9-assisted gene therapy, the cat’s immune system may be permitted to direct the infection
towards a regressive outcome. In a step towards this goal, the present study evaluates different adeno-
associated vectors (AAVs) for their competence in delivering a gene editing system into feline cells,
followed by investigations of the CRISPR/SaCas9 targeting efficiency for different sites within the FeLV
provirus. Nine natural AAV serotypes, two AAV hybrid strains, and Anc80L65, an in silico predicted AAV
ancestor, were tested for their potential to infect different feline cell lines and feline primary cells. AAV-
DJ revealed superior infection efficiency and was thus employed in subsequent transduction experiments.
The introduction of double-strand breaks, using the CRISPR/SaCas9 system targeting 12 selected FeLV
provirus sites, was confirmed by T7 endonuclease 1 (T7E1), as well as Tracking of Indels by Decomposition
(TIDE) analysis. The highest percentage (up to 80%) of nonhomologous end-joining (NHEJ) was found
in the highly conserved gag and pol regions. Subsequent transduction experiments, using AAV-DJ,
confirmed indel formation and showed a significant reduction in FeLV p27 antigen for some targets. The
targeting of the FeLV provirus was efficient when using the CRISPR/SaCas9 approach in vitro. Whether
the observed extent of provirus targeting will be sufficient to provide progressively FeLV-infected cats
with the means to overcome the infection needs to be further investigated in vivo.
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Abstract: Feline leukemia virus (FeLV) is a retrovirus of cats worldwide. High viral loads are
associated with progressive infection and the death of the host, due to FeLV-associated disease. In
contrast, low viral loads, an effective immune response, and a better clinical outcome can be observed
in cats with regressive infection. We hypothesize that by lowering viral loads in progressively infected
cats, using CRISPR/SaCas9-assisted gene therapy, the cat’s immune system may be permitted to
direct the infection towards a regressive outcome. In a step towards this goal, the present study
evaluates different adeno-associated vectors (AAVs) for their competence in delivering a gene editing
system into feline cells, followed by investigations of the CRISPR/SaCas9 targeting efficiency for
different sites within the FeLV provirus. Nine natural AAV serotypes, two AAV hybrid strains, and
Anc80L65, an in silico predicted AAV ancestor, were tested for their potential to infect different
feline cell lines and feline primary cells. AAV-DJ revealed superior infection efficiency and was
thus employed in subsequent transduction experiments. The introduction of double-strand breaks,
using the CRISPR/SaCas9 system targeting 12 selected FeLV provirus sites, was confirmed by T7
endonuclease 1 (T7E1), as well as Tracking of Indels by Decomposition (TIDE) analysis. The highest
percentage (up to 80%) of nonhomologous end-joining (NHEJ) was found in the highly conserved
gag and pol regions. Subsequent transduction experiments, using AAV-DJ, confirmed indel formation
and showed a significant reduction in FeLV p27 antigen for some targets. The targeting of the FeLV
provirus was efficient when using the CRISPR/SaCas9 approach in vitro. Whether the observed
extent of provirus targeting will be sufficient to provide progressively FeLV-infected cats with the
means to overcome the infection needs to be further investigated in vivo.
Keywords: feline leukemia virus; FeLV; CRISPR; SaCas9; AAV; provirus; gene editing; cat
1. Introduction
The impact of retroviral infections on human and animal health is of major scientific
and public interest. Although the number of HIV-related deaths has decreased continu-
ously since its peak in 2005, curative treatments for retroviral infections are nonexistent, and
it is estimated that between 480,000 and 1 million people died from AIDS-related illnesses
worldwide in 2020 [1]. Understanding the underlying biology of retroviral infections is
fundamental toward developing successful antiviral strategies, such as preventive and
therapeutic measures. The persistence of retroviral reservoirs in the cellular genome is
challenging and has not been directly targeted by commonly used antiretroviral thera-
pies (ARTs) [2] against HIV. Thus, animal models are needed to investigate host–virus
interactions and to evaluate new therapies.
As in humans, retroviral infections are prevalent in diverse animal species, including
the domestic cat. The prevalence of feline leukemia virus (FeLV; a gammaretrovirus) in-
fection varies greatly, depending on host sex, age, health, environment, and lifestyle [3].
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FeLV in cats is a well-established animal model for tumor and retroviral research that has
been used for nearly 50 years [4]. After FeLV exposure, most cats develop a regressive
FeLV infection, characterized by an early and efficient immune response, mediated by
neutralizing antibodies [5,6] and FeLV-specific cytotoxic T lymphocytes (Figure 1, [7–9]).
This remarkable feature of FeLV infection in cats yields a great opportunity to study effec-
tive antiretroviral immune responses. However, approximately one-third of cats exposed
to FeLV develop progressive FeLV infections with persistent viremia; these animals lack
effective FeLV-specific humoral and cellular immunity [10,11]. These progressively infected
cats develop fatal FeLV-associated diseases, including lymphoma, leukemia, immune sup-
pression, and anemia, and they die within a few years of infection [12,13]. Results from
an earlier study demonstrated that the different infection outcomes are associated with
differences in viral RNA and provirus tissue loads [13]. It is very rare, but possible, for
cats to raise a protective immune response and overcome persistent viremia on their own,
even months after infection. Such a full recovery from viremia has been observed in one
cat, more than one year after the onset of infection [14]. This proves that under the right
circumstances, recovery from an established progressive retroviral infection is possible.
We hypothesize that the reduction of the proviral load in cats with progressive infection
can tip the virus–host balance, in favor of the immune system of the cat; an effective
immune response may be raised and help the cat to overcome persistent viremia and evade





Figure 1. Schematic drawing of the outcomes of FeLV. In the course of FeLV infection, the virus/provirus load often
corresponds to the disease outcome. Whereas during an abortive infection the cat’s immune response successfully eliminates
viral proliferation (strong immune system: I), during progressive infection viral loads are constantly high (lack of effective
FeLV-specific humoral and cellular immunity: I). During regressive infection, an effective immune response (marked with I)
can control FeLV, often during the entire lifetime of the cat, thereby omitting FeLV-related disease and death. It is the goal
of this study to develop the tools to shift the outcome of FeLV infection from progressive to regressive, with the help of a
CRISPR/SaCas9 treatment that reduces the FeLV proviral loads in the cats’ cells and helps the immune system to overcome
viremia.
To date, no treatment regimen is known to reliably cure either progressive FeLV in-
fection in cats or other retroviral infections. Thus, new classes of therapeutics are being
developed, including the investigation and application of gene therapy. Adeno-associated
virus (AAV)-based vectors represent promising candidates for therapeutic gene transfer,
due to their lack of involvement in human diseases and their display of low immunogenic-
ity [15]. AAV has been used as a vector for over 20 years [16] in more than 100 clinical
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trials. With increasing clinical elaboration, some limitations of in vivo gene transfer, using
AAV-vectors, have been recognized. Previous infections with natural AAVs, which may
have similar or even identical capsids, compared to the gene therapy vectors, can result
in the production of cross-reactive or specific anti-AAV neutralizing antibodies (NAb),
which partially, or even completely, block transduction of the target tissue [17–19]. Thus,
the previous survey of pre-existing NAb to AAV in domestic cats laid a foundation for
future studies, leading towards gene therapy in this outbred species [20]. Compared with
the prevalence of NAb against AAV in humans, the NAb in cats were found less frequently,
ranging from 5–28%. Even lower AAV-binding Ab with neutralizing activity were de-
tected in a study in cats living in the US [21]. A low prevalence of NAb against AAV in
cats supports the usability of AAV for gene therapy in this species. However, potentially
preexisting NAb to AAV will need to be considered for individual in vivo gene therapies
in cats.
The fact that FeLV was detectable in the form of viral RNA and DNA in all 27 examined
tissues of viremic cats has important implications for the future use of AAVs as gene therapy
vectors in FeLV-infected felids [13]. Although a huge variety of AAV serotypes have been
described in the literature, so far, few studies have been performed in cats, focusing
primarily on AAV1, AAV8, AAV9, AAVrh8, AAV-B1, and AAV-AS [22–29]. Unfortunately,
none of these, so far studied, AAV serotypes fit the broad cell tropism of FeLV. Thus, one
goal of the present study was to investigate additional AAV vectors for their efficiency to
infect different feline cell lines.
Apart from finding a suitable gene therapy vector to be used in cats, a method was
developed to lower FeLV proviral loads. In the search for a tool to aid cats in overcoming
progressive FeLV infection, by lowering proviral and viral RNA loads, a recently developed
gene-editing technology was used. We employed the RNA-guided Cas9 nuclease [30–32]
from the type II prokaryotic clustered regularly interspaced short palindromic repeats
(CRISPR) adaptive immune system [33–35]. Its efficiency, accuracy, and simplicity make it
an extremely powerful tool which, when applied to the FeLV model, provides an excep-
tional opportunity to investigate new antiretroviral strategies in vitro, ex vivo, and in vivo.
The RNA-guided endonuclease Cas9 from Staphylococcus aureus (SaCas9) was selected for
the detection, cleavage, and subsequent inactivation of the FeLV provirus, due to its small
size (1053 amino acid [aa] versus 1368 aa) and the genome editing efficiencies, similar to
Streptococcus pyogenes Cas9 (SpCas9) [36].
The CRISPR/Cas9 system has a conceptually straightforward design: a single guide
RNA (sgRNA) directs the Cas9-mediated endonuclease activity to the site of interest.
The only constraint is the requirement of a specific protospacer adjacent motif (PAM) on
the target template immediately following the sgRNA target sequence. Different Cas9
orthologues have specific PAM sequence requirements. Upon complementary base pairing
of the sgRNA to the DNA target, which is PAM dependent, Cas9 produces a targeted
double-strand break in the DNA [37]. The efficacy of directing Cas9-mediated, DNA-
modification varies between sgRNAs. Reasons for this are manifold and include suboptimal
sgRNA design [38], chromatin structure, and genomic elements [39,40]. Subsequently, this
double-strand break can either be repaired by the endogenous cellular repair machinery by
nonhomologous end-joining (NHEJ), leading to local insertions and/or deletions (indels),
or via homology-directed repair when a donor template is available.
Overall, the goals of the present study were to develop the necessary tools to reduce
the FeLV proviral load in cats and, thus, give the development of an effective immune
response a chance. For this, we characterized the infectivity of various AAV serotypes
in vitro, in order to identify AAVs with broad cell tropism, corresponding to that of FeLV.
In the second step, 12 FeLV sgRNAs were identified in silico, three in each region of FeLV,
and characterized and compared in their efficiency to target and reduce FeLV provirus
reservoirs in vitro.
The use of CRISPR/SaCas9 for the deletion or deactivation of FeLV proviruses in
the cellular genome offers the possibility to reduce retroviral reservoirs in the genome
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and, with this, the potential for a cat to switch from a progressive to a regressive infection
outcome (Figure 1).
2. Materials and Methods
2.1. Cell Culture
The following cell lines were used in this study: Crandell–Rees feline kidney cells
(CRFK, ATCC CCL-94), feline embryonic fibroblasts (FEA) [41], feline astrocytes (PG-4,
ECACC 94102703), cat lung epithelial cells (AK-D, ECACC 89071903), feline mammary
carcinoma cells (MT, ECACC 12122001), feline tongue fibroblast-like cells (Fc3Tg, ECACC
90073002), feline macrophage cells (Fcwf-4, ATCC CRL-2787), human embryonic kidney
cells (HEK-293, ATCC CRL-1573), and Mus dunni tail fibroblasts (MDTF, ATCC CRL-
2017, non-infectable with FeLV). Details on the growth medium can be found in the
Supplementary Table S1.
Peripheral blood mononuclear cells (PBMCs) were isolated from left-over material
of heparin anticoagulated blood samples, submitted to our laboratory for routine diag-
nostic purposes, unrelated to this study; no additional samples or volumes were collected
for the present study. PBMCs were Ficoll-Hypaque purified (Histopaque®-1077, Sigma-
Aldrich, Buchs, Switzerland), as described [42]. Isolated PBMCs were grown at a density of
1 × 106 cells/mL in a 96 well plate (details on the media in the Supplementary Table S1).
At the initiation of the culture, expression of the IL-2 receptor was induced with 1%
phytohemagglutinin (Gibco, Thermo Fisher Scientific, Waltham, USA). One day later, re-
combinant human interleukin-2 (IL-2; Sandoz Pharmaceuticals AG, Cham, Switzerland)
was added to a final concentration of 1 ng/mL. On day 2, PBMCs were infected with AAV
vectors. All cell lines were cultured in an incubator at 37 ◦C infused with 5% CO2.
2.2. AAV Vectors and Their Infectivity In Vitro
Nine natural AAV serotypes (AAV1-9), 2 AAV hybrid strains (AAV-DJ and AAV-
DJ/8), and the ancestral Anc80L65 vector were used [43]. All AAV vectors contained
the reporter gene enhanced green fluorescent protein (EGFP), under the transcriptional
control of the human cytomegalovirus (hCMV) immediate/early gene promoter/enhancer
fragment hCMV (Appendix A, Figure A1A). The only exception was the Anc80L65 vector:
in this vector, the EGFP is under the control of the CAG promoter. All AAV vectors were
constructed, purified, and quantified by the Viral Vector Facility (VVF) at the University of
Zurich, Switzerland. AAV vectors were stored at −80 ◦C until utilized.
In order to investigate the infectivity of different AAV serotypes in cell lines (CRFK,
FEA, PG-4, AK-D, MT, Fc3Tg, Fcwf-4, FetJ, and HEK-293), as well as feline PBMCs, a
series of AAV infectivity ratios to cells (multiplicity of infection (MOI): 100 to 100,000
viral genomes (vg)/cell), were tested (always in duplicates (N = 2)). HEK-293 served as
control cell line, which had previously been shown to be infectable. Depending on the
cell line, 5 × 104–1 × 105 cells/mL, as enumerated manually using a Neubauer counting
chamber (Semadeni, Ostermundigen, Switzerland), and 1 × 106 cells/mL PBMCS, counted
using a Sysmex XT-2000iV (Sysmex Corporation, Kobe, Japan), were cultured overnight
in a 96-well tissue culture. Infection was followed by fluorescence microscopy between
days 2 and 6. Fluorescent images were captured using an inverted fluorescent microscope
(EVOS FL, Life Technologies, Waltham, MA, USA). Quantification of the mean fluorescence
intensity of the raw microscopy pictures was performed using ImageJ 1.53 k, an open
source image processing and analysis tool [44]. The signal strength ranges between 0
(black) and 255 (white).
2.3. Infection of Cells with FeLV-A/Glasgow-1 and FeLV Antigen Quantification
Various cell lines were infected with undiluted FeLV-A/Glasgow-1 supernatant from
FeLV-A/Glasgow-1-infected FEA cells. FEA, CRFK, PG-4, AK-D, MT, and M. dunni cells
(negative control) were seeded at a density of 200,000 cells per well on a 6-well plate.
Two wells contained uninfected cells as negative controls. After 24 h, the cells reached a
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confluency of 50–60%. Infection time was two hours, followed by a washing step with
the original growth medium (Supplementary Table S1). The medium was changed 24 h
after infection, and the cells were passaged in T25 flasks after 48 h. After 72 h, cells were
transferred to T75 flasks. On day 3 and day 7, the presence of FeLV p27 antigen was
determined in the supernatant, by sandwich enzyme-linked immunosorbent assay (ELISA),
as described [45]. ELISA results were calculated as a percentage, after normalization to the
positive control (culture supernatant of FL-74 feline lymphoblastoid cell line permanently
infected with FeLV), which was assayed on every plate. Values above 4% of this positive
control were considered positive [46].
2.4. Gene Editing Technology and Target Selection
The recently developed gene editing technology CRISPR/SaCas9 was employed to
investigate its potential in cutting selected target sites within the FeLV provirus. Due to
its smaller size and genome editing efficiencies, similar to SpCas9, SaCas9 was chosen
for gene editing of FeLV. Twelve target DNA sequences, T1 to T12, were selected within
the FeLV provirus, based on in silico algorithm prediction, using the software Geneious
and sgRNA Scorer 2.0, following the rules for U6 PolIII transcription and the SaCas9
PAM recognition domain (NNGRRT, Figure 2). SaCas9 enzyme cleavage stereotypically
occurs 3 bp upstream of the PAM site [36]. Minimalizing the off-target ratio and increasing
target specificity were the main goals when choosing target sites equally distributed in all
three genes of FeLV (T4–T6 in gag (group-specific antigen), T7–T9 in pol (polymerase), and
T10–T12 in env (envelope)), and T1–T3 in the long terminal repeat (LTR, Figure 2, Table 1).
All 12 sgRNAs were cloned into the plasmid px601-GFP, a gift from Yuet Wai Kan
(Addgene plasmid # 84040; http://n2t.net/addgene:84040 accessed on 21 June 2017;
RRID:Addgene_84040, [47]). In brief, SaCas9-sgRNA plasmids were constructed using
SaCas9 guides, flanked by Bsa1 sites ligated into Bsa1 cut px601-GFP. All the designed
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Figure 2. Locations of the 12 FeLV sgRNAs (T1 to T12) in the FeLV-A/Glasgow-1 genome (GenBank: KP728112.1). The three
genes, gag (group-specific antigen), pol (polymerase), and env (envelope) are flanked by the LTRs (long terminal repeats).
Three target DNA sequences were chosen in gag (T4–T6), pol (T7–T9), env (T10–T12), and LTR (T1–T3), each marked with an
arrow. The size of the genes and the LTRs is proportional to the genome size; arrows mark the location of the target, but
their size is not to scale. Numbers below the schematic of the genome represent the beginning and end of the LTRs, as well
as the beginning of each gene.
2.5. Transfection
FeLV-A/Glasgow-1-infected cells (200,000 cells; CRFK, PG-4 or FEA) were seeded in
duplicates in 6-well plates. The next day, the cells were transfected, when confluency was
around 50%, with 2.5 µg plasmid DNA, using LipofectamineTM 3000 reagent (Invitrogen,
Thermo Fisher Scientific), according to the manufacturer’s protocol.
Successful transfection of the SaCas9-EGFP-TX was confirmed by the microscopic
detection of the EGFP expression after two days. Using this protocol, the transfection
efficiency obtained was around 5% for CRFK cells and 20–30% for PG4 and FEA cells.
Despite optimization (variations in plasmid und Lipofectamine concentrations, electropo-
ration, instead of chemical transfection), the transfection efficiency could not be further
improved; therefore, the transfected cells were trypsinized, washed, and collected in PBS
before sorting, based on their EGFP-signal, using a FACS analyzer (BD Aria III at the
Cytometry Facility, University of Zurich, Switzerland). Duplicates had to be combined to
collect >200,000 cells per sample.
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Table 1. Selected SaCas9 target sites, PCR primers and conditions.
Target Direction 1 Sequence Amplification Primers Annealing PCR Size T7E1 Cut
Target 1 as TTATATCTCATGGGAACATAC 907_F: CCCCTACCCCAAAATTTAGCC 64 ◦C 456 bp 386 bp
GTATGTTCCCATGAGATATAA 1710_R: GTCTTCCTCGGCGATGAGAC 70 bp
Target 2 s GAGGCCAAGAACAGTTAAACC 907_F: CCCCTACCCCAAAATTTAGCC 64 ◦C 456 bp 296 bp
GGTTTAACTGTTCTTGGCCTC 1710_R: GTCTTCCTCGGCGATGAGAC 160 bp
Target 3 s TCTCCAGGCTCCCCAGTTGAC 907_F: CCCCTACCCCAAAATTTAGCC 64 ◦C 456 bp 229 bp
GTCAACTGGGGAGCCTGGAGA 1710_R: GTCTTCCTCGGCGATGAGAC 227 bp
Target 4 as TGCGGCGAAAGAGGTTGAGGG 1229_F: GAAACCGTCATGGGCCAAAC 65 ◦C 714 bp 373 bp
CCCTCAACCTCTTTCGCCGCA 1366_R: AGTTAGGGCCACTGGATCTT 341 bp
Target 5 s CCTGACAGGCGAAGAAAGGCA 1365_F: CAACAACCGACCCCAGTATT 65 ◦C 410 bp 224 bp
TGCCTTTCTTCGCCTGTCAGG 1691_R: CAACCTGCTTTACCTGTGCC 186 bp
Target 6 as TAGTAATGTAAGGAACTTGGT 1229_F: GAAACCGTCATGGGCCAAAC 65 ◦C 449 bp 244 bp
ACCAAGTTCCTTACATTACTA 1230_R: GAGGAAGGATCAGGCGGTAAC 205 bp
Target 7 s TTATACCGGGTACGTAACACG 1248_F: CCGGAACACATTGGGAAG 61 ◦C 909 bp 496 bp
CGTGTTACGTACCCGGTATAA 1251_R: CCCACCAGAAACGCTAAG 413 bp
Target 8 as GTACCAAGGGTGAGACGGCGG 1236_F: GGTATGGGAATGGCTCATTGTC 61 ◦C 532 bp 223 bp
CCGCCGTCTCACCCTTGGTAC 1240_R: GGTACCTTACCCTGAAATCG 309 bp
Target 9 s TATGCCCCATGAAGCGTACCA 1236_F: GGTATGGGAATGGCTCATTGTC 61 ◦C 532 bp 431 bp
TGGTACGCTTCATGGGGCATA 1240_R: GGTACCTTACCCTGAAATCG 101 bp
Target 10 s ATTTAGTCCCCAGAAAAAGGG 1543_F: CCAACAGGGATGGTTTGAAG 61 ◦C 530 bp 267 bp
CCCTTTTTCTGGGGACTAAAT 1544_R: CGGAAGGTCGAACTCTGGTC 263 bp
Target 11 as GGGACACCGTGAATAAAGCGA 1662_F: CAAAGGGAACACATTGTGGA 61 ◦C 566 bp 308 bp
TCGCTTTATTCACGGTGTCCC 1668_R: ATAGGGTGGTCGAGAAACCA 258 bp
Target 12 s GGCTCTGTGCCGCATTGAAAG 1666_F: AGCTGTCAGGTTCCGAAGAG 62 ◦C 497 bp 287 bp
CTTTCAATGCGGCACAGAGCC 1669_R: GGCCGAAGAGGAGAATTAGG 210 bp
1 Direction of the target: s: sense; as: anti-sense.
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2.6. Nucleic Acid Extractions and TaqMan Fluorogenic Real-Time PCR Assay
Genomic DNA (gDNA) was extracted from cells using a DNeasy Blood & Tissue Kit
(Qiagen, Hombrechtikon, Switzerland), following the manufacturer’s recommendations,
with an elution volume of 100 µL per sample. For all nucleic acid extractions, negative
controls, consisting of 100 µL of phosphate-buffered saline (PBS), were prepared with each
batch to monitor cross contamination.
The gDNA was amplified and quantified on an ABI Prism 7700 sequence detection
system (Applied Biosystems), and copy numbers were determined using corresponding
standards, generated from serial dilutions of a synthetic oligonucleotide. Negative ex-
traction controls, as well as water controls, served as negative controls. FeLV provirus
loads were quantified by TaqMan real-time PCR (U3 region) [48]. As two LTR U3 target
sequences are present for each FeLV provirus copy, the number of provirus copies was
calculated by dividing the number of copies of U3 (as determined by real-time PCR (qPCR))
by two. This number of provirus copies was then divided by the number of feline albumin
(fALB) copies, measured by qPCR, as described previously [49], to determine the provirus
copy numbers per cell.
2.7. CRISPR Efficiency Analysis by T7 Endonuclease 1 (T7E1) Mismatch Detection Assay and
Tracking of Indels by Decomposition (TIDE)
Heteroduplexes representing nucleotide mismatches, as a result of NHEJ after SaCas9
cleavage, were detected and located by the application of T7E1 [50]. T7E1 is a structure-
selective enzyme that detects structural deformities in heteroduplexed DNA (mismatches)
and, thus, can be used as a method to evaluate CRISPR-Cas9-mediated gene editing [50].
In order to carry this out, a conventional PCR was performed on gDNA extracted from
CRISPR/SaCas9-treated cells and control cells, with primers spanning each CRISPR/SaCas9
sgRNA target region (Figure 2). Genomic DNA (gDNA) was extracted from cells using
a DNeasy Blood & Tissue Kit (Qiagen), following the manufacturer’s recommendations,
with an elution volume of 100 µL per sample. For all nucleic acid extractions, negative
controls consisting of 100 µL of phosphate-buffered saline (PBS) were prepared with each
batch to monitor cross contamination. Sequences for the forward and reverse primers, as
well as the cycling conditions, are depicted in Table 1. Conventional PCR was performed in
a thermocycler (PCR-Gradient-Thermocycler, Biometra, Jena, Germany) using Phusion Hot
Start II High-Fidelity DNA-Polymerase (Thermo Fisher). The resulting PCR products were
visualized on an agarose gel, which was followed by the determination of CRISPR/SaCas9
cleavage efficiency by T7 Endonuclease 1 (T7E1, BioConcept, Allschwil, Switzerland) di-
gestion, according to the manufacturer’s recommendations. In brief, 200 ng of purified
PCR product (MinElute PCR Purification Kit (Qiagen)) of the sgRNA target region was
denatured at 95 ◦C for 5 min and re-annealed by subsequent slow cooling at −2 ◦C per
second to 85 ◦C, followed by a −0.1 ◦C per second to 25 ◦C. In the case of CRISPR/SaCas9
cleavage, followed by aberrant NHEJ, heteroduplexes were formed (e.g., between mutant
and wild-type (WT) amplicons). A T7E1 digestion followed immediately, detecting these
structural deformities. The efficiency of T7E1 cleavage was determined by comparing
control and experimental samples on 2% agarose gels (Fusion software) and on a fragment
analyzer (FA; 5200, Agilent, Santa Clara, CA, USA) using the dsDNA 935 Reagent Kit
(Agilent), based on the size of DNA fragments, ranging from 1 to 1500 bp, using the ProSize
3.0 software. Both detection systems compared band intensities between the control and
the cut sample.
SaCas9-mediated NHEJ efficiency was calculated based on the fraction of cleaved DNA:




(a + b + c)
) (1)
with a and b being the cleaved DNA and c being the uncut DNA [51].
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The spectrum and frequency of small indels generated by targeted genome editing
tools, such as CRISPR/Cas9, can also be determined by two standard capillary sequencing
reactions (wild type and edited sample), followed by sequence comparison using an online
R based program [52]. Sanger traces were generated by Microsynth, with target-specific
PCR products (Table 1), and analyzed with the TIDE webtool ([52]; http://shinyapps.
datacurators.nl/tide/ accessed on 16 June 2020). Default parameters were used for the
analysis, with the exception of the indel size range, which was set from 10 to 20 bp.
2.8. Production, Purification and Quantification of Single-Stranded (ss) AAV Vectors
The sgRNA4, sgRNA5, sgRNA6, sgRNA8, and sgRNA10 were cloned into the plas-
mid pX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA (a gift from Feng
Zhang (Addgene plasmid #61591; http://n2t.net/addgene:61591 (accessed on 21 June
2017); RRID:Addgene_61591; [36]). These plasmids contain a human codon-optimized
SaCas9, driven by a cytomegalovirus (CMV) promoter, and a U6-driven sgRNA. In brief,
plasmids were constructed, using guides flanked by Bsa1 sites ligated into Bsa1 cut #61591.
These #61591/SaCas9 plasmids were propagated, amplified, and purified using a commer-
cial kit, following the manufacturer’s protocols (NucleoBond Xtra Midi, Macherey Nagel,
Fisher Scientific AG, Oensingen, Switzerland). All the designed plasmids were verified by
Sanger sequencing (Microsynth).
Single-stranded (ss) AAV vectors were produced and purified, as previously de-
scribed [53,54]. Briefly, HEK 293 cells [55], expressing the simian virus (SV) large T anti-
gen [56] (293T), were transfected by polyethylenimine (PEI)-mediated cotransfection of
AAV vector plasmids (providing the to-be packaged AAV vector genome), the AAV helper
plasmid p61 (Cell Biolabs, Inc., San Diego, CA, USA; VPK-420-DJ; p61 providing the AAV
serotype 2 rep proteins and the cap proteins of AAV-DJ), and adenovirus (AV) helper
plasmids pBS-E2A-VA-E4 [57] (providing the AV helper functions) in a 1:1:1 molar ratio.
At 120 to 168 h post-transfection, HEK 293T cells were collected and separated from
their supernatant by low-speed centrifugation. AAV vectors, released into the supernatant,
were PEG precipitated over night at 4 ◦C by adding a solution of polyethylene glycol 8000
(8% v/v in 0.5 M NaCl) and completed by low-speed centrifugation. Cleared supernatant
was discarded, and the pelleted AAV vectors were resuspended in AAV resuspension
buffer (150 mM NaCl, 50 mM Tris HCl, pH 8.5). HEK 293T cells were resuspended in AAV
resuspension buffer and lysed by Bertin’s Precellys Evolution homogenizer, in combina-
tion with 7 mL soft tissue homogenizing CK14 tubes (Bertin). The crude cell lysate was
DENARASE (c-LEcta GmbH) treated (150 U/mL, 90 to 120 min at 37 ◦C) and cleared by
centrifugation (10 min at 17,000× g/4 ◦C). The PEG precipitated (1 h at 3500× g/4 ◦C)
AAV vectors were combined with the cleared cell lysate and subjected to discontinuous
density iodixanol (OptiPrep™, Axis-Shield, Kampenhout, Belgium) gradient (isopycnic)
ultracentrifugation (2 h 15 min at 365,929× g/15 ◦C). Subsequently, the iodixanol was
removed from the AAV vector containing fraction by 3 rounds of diafiltration using Vi-
vaspin 20 ultrafiltration devices (100,000 MWCO, PES membrane, Sartorius, Göttingen,
Germany) and 1× PBS supplemented with 1 mM MgCl2 and 2.5 mM KCl, according to the
manufacturer’s instructions. The AAV vectors were stored aliquoted at −80 ◦C.
Encapsidated viral vector genomes (vg) were quantified using the Qubit™ 3.0 fluorom-
eter, in combination with the Qubit™ dsDNA HS Assay Kit (both Life Technologies). Briefly,
5 µL of undiluted (or 1:10 diluted) AAV vectors was prepared in duplicate. Untreated
and heat-denatured (5 min at 95 ◦C) samples were quantified, according to the manufac-
turer’s instructions. Intraviral (encapsidated) vector genome concentrations (vg/mL) were
calculated by subtracting the extraviral (non-encapsidated; untreated sample) from the
total intra- and extraviral (encapsidated and non-encapsidated; heat-denatured sample).
Constructed AAV vectors (vT4 with sgRNA4 [vKHH1], vT5 with sgRNA5 [vKHH3], vT6
with sgRNA6 [vKHH4], vT8 with sgRNA8 [vKHH2], and vT10 with sgRNA10 [vKHH5])
had vector genome concentrations between 4.4 × 1012 vg/mL and 1.0 × 1013 vg/mL
(Appendix A, Figure A1B).
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The identity of encapsidated genomes was verified and confirmed by Sanger DNA
sequencing of amplicons, produced from genomic AAV vector DNA templates (identity
check). Vectors were stored at −80 ◦C.
All AAV vectors were produced by the VVF at the University of Zurich.
2.9. Transduction of AAV- SaCas9 Vectors
FeLV-A/Glasgow-1-infected CRFK (5.0 × 104 cells/well), FEA (2.5 × 104 cells/well),
and PG-4 (5.0 × 104 cells/well) cells were seeded in 24-well tissue culture plates. After
24 h, cells were transduced in triplicates with vT1-5 and v426, a control AAV-DJ/SaCas9
vector without sgRNA, at an MOI of 10,000. Three wells per cell line were not transduced
with the AAV vectors (control cells). On day 3, cells and supernatant were collected from
each well.
2.10. Statistics
Statistical analyses were performed using GraphPad Prism for Windows, Version 8.4.3
(GraphPad Software, San Diego, CA, USA). Differences among three and more groups
were tested for significance using the non-parametric Kruskal–Wallis one-way ANOVA by
Ranks (pKW) for unpaired samples, followed by the Dunn’s Multiple Comparison test (pD).
Percentage NHEJ, determined by TIDE and T7E1, was analyzed using the Spearman rank
test for correlation. A p-value < 0.05 was considered significant.
3. Results
3.1. Cell Tropism of AAV Serotypes
The infectivity of 12 EGFP-expressing AAV serotypes (Appendix A, Figure A1) was
analyzed by transducing different cell lines, as well as feline PBMCs. We were able to
infect most cell lines investigated, with AAV-DJ being by far the most efficient in vitro
(Figure 3 shows a representative infection of CRFK cells; the results using other cell lines
can be found in Appendix A, Figure A2A–H; Figure 4, and a numeric summary, is given
in Table 2). While AAV-DJ was able to infect CRFK and Fcwf-4 cells already at an MOI
of 100, the majority of FEA cells were infectable at an MOI of 500. Although all other
feline cell lines needed a higher MOI for an efficient infection, AAV-DJ was able to infect
all investigated infectable cell lines more efficiently than the other AAV serotypes. While
AAV2 and AAV4 also infected several of the cell lines efficiently (Figure 4, Table 2), AAV5,
AAV7, AAV8, AAV9, AAV-DJ/8, and Anc80L65 clearly showed less potential for infection
in a broad variety of feline cell lines. AAV1, AAV3, and AAV6 showed efficient infection in
two or more feline cell lines, thereby revealing an intermediate infection pattern. The T
lymphocytic cell line, FetJ, and feline PBMCs could not be infected with the AAV serotypes
and the MOIs used in the present study (Figure 4I, Appendix A, Figure A2G, and data
not shown). Thus, even at an MOI of 100,000, none of the included AAV serotypes were
able to infect FetJ cells or PBMCs, at least not to a level where any clear EGFP-signal was
detectable.
When comparing the infectability of cell lines, CRFK and HEK cells were clearly the
ones which were most easily infected, followed by Fcwf-4 and FEA. With the exception of
FetJ and fPBMCs, all cell lines were infectable by at least some AAV vectors. In general, a
dose-dependent expression of EGFP could be observed, with low MOIs showing the least
expression and high MOIs showing the highest expression. AAV-DJ clearly showed the
highest infectivity of the feline cells tested, followed by AAV2 and AAV4.








≥ ≥ ≥ ≥
≥50%.
Figure 3. Fluorescent microscopy images of CRFK cells infected with 12 AAV serotypes after three days. Infection of
nine natural AAV serotypes (AAV1-9), two AAV hybrid strains (AAV-DJ and AAV-DJ/8), and Anc80L65, all EGFP tagged
from the upper left to the lower right, using a multiplicity of infection (MOI) between 100 and 10,000. From the left to
the right of each column, the MOI consisted of 100, 500, 1000, 5000, and 10,000, always in duplicates (N = 2). Red squares
mark the minimal MOI, at which a significant AAV infection could be visualized for each AAV serotype by fluorescence
(corresponding to ≥ 50% infection). For AAV7, AAV8, AAV-DJ/8, and Anc80L65, no infection could be observed up to an
MOI of 10,000. The bars represent 400 µm.
Table 2. Summary of in vitro infectivities of various AAV serotypes in different cell lines and fPBMCs depicted as multiplicity
of infection (MOI) a.
HEK CRFK FEA PG-4 AK-D MT Fc3Tg Fcwf-4 FetJ fPBMC
AAV1 500 10,000 >10,000 100,000 100,000 ≥50,000 >50,000 >10,000 >100,000 >100,000
AAV2 500 500 10,000 10,000 10,000 5000 25,000 1000 >100,000 >100,000
AAV3 1000 10,000 10,000 100,000 >100,000 25,000 ≥50,000 5000 >100,000 >100,000
AAV4 1000 1000 5000 50,000 10,000 ≥50,000 25,000 1000 >100,000 >100,000
AAV5 5000 5000 >10,000 >100,000 >100,000 >50,000 >50,000 >10,000 >100,000 >100,000
AAV6 5000 5000 10,000 100,000 100,000 ≥50,000 > 50,000 ≥10,000 >100,000 >100,000
AAV7 ≥10,000 >10,000 >10,000 >100,000 >100,000 >50,000 >50,000 >10,000 >100,000 >100,000
AAV8 5000 >10,000 >10,000 >100,000 >100,000 >50,000 >50,000 >10,000 >100,000 >100,000
AAV9 5000 10,000 >10,000 >100,000 >100,000 >50,000 >50,000 >10,000 >100,000 >100,000
AAV-DJ 100 100 500 5000 5000 2500 2500 100 >100,000 >100,000
AAV-DJ/8 10,000 >10,000 >10,000 >100,000 >100,000 >50,000 >50,000 >10,000 >100,000 >100,000
Anc80L65 50,000 ≥50,000 100,000 >100,000 ≥100,000 ≥50,000 >50,000 ≥10,000 >100,000 >100,000
a Each cell line was infected with serial dilutions of various AAV serotypes expressing an EGFP reporter gene. Infectious titers were
determined by evaluating EGFP-expressing cells after 3 days, apart from Anc80L65, where the EGFP-signal often increased until day 5.
Thus, MOIs shown for Anc80L65 represent day 5. The MOIs depicted here display the lowest MOI with a significant fluorescence, showing
an infectivity of ≥50%. AAV serotypes that are highly efficient at infecting a particular cell line are shown in bold.
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Figure 4. Quantification of the mean fluorescence signal intensity of cells infected with 12 AAV serotypes. (A) HEK (MOI of
10,000), (B) CRFK (MOI of 10,000), (C) FEA (MOI of 10,000), (D) PG-4 (MOI of 100,000), (E) AK-D (MOI of 100,000), (F) MT
(MOI of 50,000), (G) Fc3Tg (MOI of 50,000), (H) Fcwf-4 (MOI of 10,000), and (I) Fet-J (MOI of 100,000) cells infected in
duplicates (N = 2), with 12 AAV serotypes, all EGFP tagged. Mean signal intensity is shown for the highest MOI applied
in the respective cell line, ranging from 10,000 to 100,000 on day 3. The signal strength ranges between 0 (black) and
255 (white).
3.2. FeLV-A/Glasgow-1 Infection of Feline Cell Lines
FEA, CRFK, and PG-4 cells were successfully infected with FeLV-A/Glasgow-1 dis-
playing p27 antigen levels > 100% three to seven days after infection. Other feline cell
lines, such as MT and AK-D, showed low p27 antigen levels (<8% and <3%, respec-
tively; Figure 5). Thus, all following experiments, to target FeLV provirus using the
CRISPR/SaCas9 system, were performed with FEA, CRFK, and PG-4 cells.
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Figure 5. Comparison of FeLV-A/Glasgow-1 infection in various feline cell lines. FeLV p27 antigen
levels, as determined by ELISA, after three and seven days. The non-infectable M. dunni cell line was
used as a negative control. * Due to the extremely high p27 levels in PG-4 cells, the value depicted
only represents day three.
3.3. Validation of CRISPR/SaCas9 Targets by Transfection
Lipofectamine transfection of the different CRISPR/SaCas9 plasmids containing sgR-
NAs targeting sites within the FeLV provirus resulted in low transfection efficiency, which
ranged from 3% (CRFK) to 20–30% (PG-4 and FEA cells). Therefore, a FACS-based cell en-
richment assay was performed, where cells successfully transfected with SaCas9-EGFP-TX
were collected, based on a medium to high EGFP signal.
Each target region in the FeLV provirus was amplified with a primer pair specific for
exogenous FeLV. Endogenous FeLV (enFeLV) was not detectable in non-infected cell lines
using these PCR systems, confirming the specificity of the primers for exogenous FeLV.
The SaCas9 cleavage efficiency of the different sgRNAs was visualized after T7E1
cleavage on agarose gels, confirming the successful targeting at all 12 locations in the
FeLV provirus (NHEJ frequency and representative results can be found in Appendix A,
Figure A3). Additionally, T7E1 cleavage was determined by parallel capillary electrophore-
sis using a FA. An overview of the calculated NHEJ from the cleavage efficiency, using both
the FA and band intensity comparison, is depicted in Figure 6A, Appendix A, Figure A3A,
and Table 3. The majority of NHEJ in the sorted cells ranged between 6 and 27%, with
targets in the gag and pol region (T4–T8) being generally higher than in the other regions of
the FeLV provirus.
Table 3. Percentage cleavage efficiency of FeLV provirus at target sites after transfection.
Target
CRFK FEA PG-4
TIDE FA 1 Gel TIDE FA Gel TIDE FA Gel
T1 8.2 8.1 0.0 10.5 10.7 7.5 4.6 4.5 5.9
T2 21.3 14.6 15.1 27.5 16.1 8.3 12.2 7.6 14.0
T3 11.8 7.3 12.8 9.8 6.3 5.1 9.1 3.6 1.5
T4 62.6 16.9 28.6 60.8 24.6 30.0 41.3 21.0 22.5
T5 57.2 29.9 30.0 81.5 43.7 25.2 31.5 25.6 14.0
T6 42.5 21.6 27.2 45.6 17.6 16.3 16.9 20.0 18.8
T7 68.0 13.3 14.0 74.5 12.0 10.6 39.0 26.2 15.1
T8 79.4 10.0 26.5 85.8 30.0 23.8 38.4 28.5 14.6
T9 10.1 6.7 18.8 26.0 11.7 11.7 9.8 10.8 11.7
T10 43.7 14.4 14.6 48.6 12.3 9.4 34.3 12.1 9.4
T11 N.A. N.A. N.A. 40.1 17.1 12.3 14.1 7.1 6.2
T12 21.4 13.7 9.4 17.7 8.8 8.9 8.9 6.7 10.0
1 FA: Fragment Analyzer; N.A. not available.
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Figure 6. NHEJ frequency in CRFK, FEA, and PG-4 cells using CRISPR/SaCas9 editing for 12 FeLV
targets and analyzed with the T7E1 and TIDE assay. After CRISPR/SaCas9 transfection and cell
sorting, all 12 target regions within FeLV were amplified and analyzed using either the T7E1 assay
measured by FA (A) or TIDE (B). Cleavage frequency, as determined by FA, was calculated into %
NHEJ. Three cell lines (CRFK, FEA, and PG-4) are shown for each target and plotted against their %




), with a and b being the cleaved DNA and c being
the uncut DNA [51]). For target 11, there were not enough CRFK cells for cell sorting available.
Spearman correlation coefficients were determined to assess the linear relationship
between %NHEJ, determined by T7E1 cleavage using a FA and visualization on an agarose
gel. In all three cell lines, a linear relationship was found between the two methods for
analyzing the T7E1 cleavage efficiency (CRFK: r = 0.6182, p = 0.0478; FEA: r = 0.8671,
p = 0.0005; PG-4: r = 0.8091, p = 0.0022).
Additional knowledge about the indel spectrum and relative frequency, after CRISPR/
SaCas9 editing, was gained by TIDE analysis [51]. In general, TIDE analysis revealed a
similar pattern, with highest NHEJ in the gag and pol region (Targets 4–8) and lowest in
the LTR (Targets 1–3). An overview of the determined overall efficiency can be found in
Figure 6B and Table 3. Generally, higher % NHEJ were calculated by TIDE, in comparison
to the T7E1 assay. Targets with low % NHEJ, determined by TIDE (T1, T2, T3, and T9),
mostly showed a narrow indel distribution, meaning that indels mainly consisted of a single
deletion or insertion (−1 to +1 bp). Targets which seemed more efficiently cleaved tended
to show broader mutation patterns with indels of frequently −10 to +3 bp. Interestingly,
the broadest indel spectrum was observed in the Target T8: a broad peak was observed
between around −10 to +1 bp, with highest indel rate at −2 bp, with around 24% for CRFK
and FEA cells.
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Due to the promising results found in targets in the gag and pol region, further evalua-
tion was attempted by the production of gene therapy vectors containing the gene editing
construct, as well as a chosen target site.
3.4. CRISPR/SaCas9 Activity on the Different FeLV Targets Using AAV-DJ as Gene
Therapy Vector
Based on the superior transduction efficiency (Figures 3 and 4, Table 2, and Appendix A,
Figure A2A–G), AAV-DJ, an AAV hybrid strain, was selected as the delivery vector for
SaCas9-sgRNA. In order to ensure the highest possible transduction rates, an MOI of
10,000 was chosen for all the transduction experiments. FeLV-A/Glasgow-1-infected
CRFK, FEA, and PG-4 cells were transduced with AAV-CRISPR/SaCas9 vectors either
with a FeLV-specific sgRNA-sequence (Targets 4, 5, 6, 8, and 10) or without (control AAV-
CRISPR/SaCas9 without target sequence: v426, Appendix A, Figure A1B).
The CRISPR/SaCas9 activity, on the various target sites, was evaluated using the T7E1
mismatch detection system and the TIDE analysis (Figure 7 and Table 4). The TIDE analysis
resulted in less variations within the triplicates of a target, compared to the T7E1 analysis
by FA or on a gel (Figure 7, Table 4, details in Appendix A; Figures A4 and A5).
 
Figure 7. Comparison of CRISPR/SaCas9 activity leading to indels after transduction. After CRISPR/SaCas9 transduction
using the AAV-DJ vectors vT4 (Target 4, blue), vT5 (Target 5, yellow), vT6 (Target 6, red), vT8 (Target 8, green), and vT10
(Target 10, grey); NHEJ events were compared using TIDE and the T7E1 assays. T7E1 efficiency was determined by parallel
capillary electrophoresis using a fragment analyzer (FA) and band intensity comparison on an agarose gel. Transductions
were performed on CRFK, FEA, and PG-4 cells. Data represent the mean of three biological replicates ± standard deviation.
Table 4. In vitro cleavage of FeLV provirus at target sites after transduction.
Target
CRFK FEA PG-4
TIDE FA 1 Gel TIDE FA Gel TIDE FA Gel
T4 (vT4) 49.17 53.63 39.18 12.17 27.71 28.86 13.30 23.83 27.37
T5 (vT5) 58.90 43.25 31.86 34.27 41.14 36.30 18.30 29.03 34.94
T6 (vT6) 32.07 35.48 25.23 13.00 16.07 15.58 4.43 7.62 15.98
T8 (vT8) 81.60 37.15 40.97 47.87 43.54 35.92 44.50 44.96 34.25
T10 (vT10) 32.00 17.48 18.41 7.50 5.26 13.33 2.73 1.18 5.96
The mean frequency of indels of the triplicates is depicted. 1 FA: Fragment Analyzer. In bold are the highest and lowest percentages
of NHEJ.
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Using the TIDE analysis, the frequency of indels varied between 2.7% (for T10 in PG-4)
and 81.6% (T8 in CRFK), by FA between 1.2% (for T10 in PG-4) and 53.6% (T4 in CRFK)
and by gel between 6% (for T10 in PG-4) and 41% (T8 in CRFK), confirming the successful
introduction of indels (Table 4).
Statistically significant, higher indel frequency was found in Target 8, compared to
Target 10 for the TIDE analysis, in all three cell lines and in the T7E1 analysis by FA in
FEA and PG-4 cells (Appendix A, Figure A4). With the exception of the TIDE analysis of
Target 4 in FEA cells, Targets 6 and 10 always showed the lowest frequency of indels in
all analyses.
A comparison between the frequency of indels between the different cell lines within
one target showed a tendency of a higher percentage in CRFK cells, compared to FEA and
PG-4 cells (Appendix A, Figure A5). Statistically significant differences between CRFK and
PG-4 cells were observed for the TIDE analysis for Targets 5, 6, and 10, as well as for the
T7E1 analysis by FA for Targets 4, 6, and 10.
Spearman correlation coefficients were determined to assess the linear relationship
between %NHEJ, revealed by T7E1 cleavage using a FA and visualization on an agarose gel.
A linear relationship of r = 0.832 with p < 0.0001 was calculated. A significant correlation
could also be shown between the TIDE and T7E1, analyzed by FA, as well as between
the TIDE and T7E1, analyzed by gel: r = 0.873 and p < 0.0001; r = 0.721 and p < 0.0001,
respectively.
3.5. Reduction of FeLV Antigen in Different Cell Lines by AAV Transduction
The transduction of the three cell lines with the gene therapy vectors vT4, vT5, vT6,
VT8, and vT10 resulted in a significant reduction in FeLV p27 antigen (Figure 8). Gene
therapy vectors vT4 and vT5 showed a statistically significant reduction in p27 antigen,
by up to 71%, compared to untreated cells in all three cell lines (vT4: CRFK: p < 0.0001;
FEA: p = 0.0306; PG-4: p < 0.0001; vT5: CRFK: p = 0.0245; FEA: p = 0.0094; PG-4: p = 0.0373).
Additionally, FeLV p27 antigen levels were significantly reduced by using vT8, leading to a
reduction of 67% in CRFK and 47% in PG-4 cells (p = 0.019 and p = 0.0228, respectively),
whereas vT6 showed only a statistically significant reduction in p27 antigen levels in FEA
cells (p27 antigen reduction of 50%, p = 0.0459, Figure 8). Target 10, which directs SaCas9 to









Figure 8. FeLV p27 antigen levels, after transduction in supernatant of CRFK (A), FEA (B), and
PG-4 (C) cells. Comparison of FeLV p27 antigen levels after transduction with the AAV-DJ vector
without target (v426), Target 4 (vT4), Target 5 (vT5), Target 6 (vT6), Target 8 (vT8), Target 10 (vT10),
and non-transduced cells (negative). Since several individual experiments were compared, ultimate
normalization of p27 values was performed to the p27 means of the non-transduced control cells
(equaling 100%). FeLV p27 antigen levels were tested for significant differences by Kruskal–Wallis
one-way ANOVA by ranks (pKW as indicated) and subsequently by Dunn’s post-test: * = p < 0.05;
** = p < 0.01; **** = p < 0.0001. The data are shown as box plots; the boxes extend from the 25th to 75th
percentiles. The horizontal line represents the median, and the whiskers extend from the smallest to
the largest value.
4. Discussion
The persistence of retroviral reservoirs in the cellular genome is a major obstacle to
curing retroviral infections in animals, as well as in humans. Recent technologies have
provided the means to target retroviruses in their most hidden state—as a provirus. Thus
far, retroviral treatments generally focused on the virus, thereby allowing the provirus,
hidden in the host, to thrive. With the discovery of CRISPR, a highly specific, easily
programmable gene editing technology, the goal of deleting or deactivating the provirus
itself has become a possibility. In contrast to HIV (a lentivirus), the sequence of FeLV
(a gammaretrovirus) is highly conserved throughout infection [58]. Because the efficacy
of the CRISPR/Cas9 system is largely dependent on sgRNA matching the target viral
DNA, its application should, thus, be even more effective for FeLV. While we recognize
that differences exist between FeLV gammaretrovirus infection in cats and HIV lentivirus
infection in humans, this natural animal model may still yield proof-of-concept results, in
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support of the efficiency of using the CRISPR/Cas9 system to target retroviral provirus
sequences and reduce proviral loads in vitro and in the future in vivo in an outbred animal
species. In addition, after natural FeLV infection, most naïve cats can mount successful
immune responses. These cats are regressively infected with either no or only transient
viremia and subsequent suppression of virus replication and the absence of development
of FeLV-associated diseases. Thus, it may not be necessary to target and destroy every
provirus in progressively infected cats. Rather, by reducing (pro)virus levels, the immune
system of the cat may be able to take the lead and suppress the remaining virus.
Among the various strategies for the transport of bioreactive molecules, AAV has stood
out, due to its broad variety of available vectors, safety, and low induction of immunologic
reactions. A constantly increasing amount of AAV serotypes has been discovered, as well
as designed, addressing various features. In the first step, AAV vectors needed to be found
to specifically target cells containing FeLV provirus. Thus, in this study, we systematically
tested the infectivity of various AAVs in different feline cell lines (as a model for different
feline tissues) for their ultimate application as suitable gene therapy vectors. The receptor
of FeLV-A, fTHTR1, the thiamine transport protein 1, was found in a broad variety of
tissues, with highest levels in sites of FeLV entry and shedding [59,60]. Consequently,
FeLV has a very broad cell target spectrum and, thus, a vector that targets many different
feline tissues was sought. Various AAV vectors were tested in vitro for a matching tropism.
Differences between cell lines, as well as AAV serotypes, were obvious. AAV-DJ, a hybrid
strain, was clearly superior in infecting a broad range of cell lines. AAV-DJ had been
designed using a DNA family shuffling technology, with the goal of improving the desired
qualities of multiple AAV isolates [61]. Similar to earlier results in human cell lines [61],
AAV-DJ was superior in its in vitro infectivity to all tested AAV serotypes in feline cell
lines. With the exceptions of FetJ and fPBMCs, AAV-DJ could infect all tested cell lines.
Similar findings had already been described for human monocytes and dendritic cells
where other serotypes, namely, AAV-1 and AAV-6, outperformed AAV-DJ [61]. Thus, virus
infectivity in vitro might not necessarily reflect the FeLV tropism in vivo completely, since
AAV-DJ lacked the ability to infect T-lymphocytes and fPBMCs. Therefore, additional AAV
serotypes, or other vectors, potentially need to be screened in further studies to gain access
to all target cells of FeLV.
When potential target sites were chosen for this study, each region in the FeLV, corre-
sponding to the LTR, pol, gag, and env, was addressed. These sites were chosen, according
to their suitability, based on in silico algorithm prediction and the presence of the SaCas9
PAM site. Moreover, they were checked for potential sequence identity to the feline genome.
None of the 12 targets revealed sequence identity within the coding region to the cat’s
genome. Two of the targets (Target 2 and 10) did not reveal sequence identity to the cat’s
genome at all (including non-coding sequences). In contrast, Target 7, located in the pol
region of FeLV, showed sequence similarity with enFeLV-like sequences. Domestic cats,
and related small felids (genus Felis), harbor enFeLV in their genome: footprints of an-
cient retroviral infections [62,63]. Endogenous retroviruses are a highly diverse group of
elements, with a gene organization closely related to that of exogenous retroviruses [64].
Although the transcription and translation of enFeLV has been demonstrated in healthy
cats and in feline cell lines, enFeLV are typically incapable of giving rise to infectious
virus particles [65,66]. An association between enFeLV loads and FeLV replication was
demonstrated in domestic cats, where only five of ten cats with high enFeLV loads, but
nine of ten cats with low enFeLV loads, developed progressive FeLV infection [67]. The
later observation was subsequently substantiated, when a significant association between
enFeLV loads and the infection outcome was found in another experimental study: cats
that developed regressive infection had significantly higher enFeLV loads than cats that
developed progressive FeLV infection [68].
Not only in domestic cats, but also in pumas, has it been shown that endogenous viral
elements negatively correlate with FeLV susceptibility [63]. It was hypothesized that, due
to the absence of enFeLV in felids outside the genus Felis, more severe disease consequences
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might, therefore, be observed [63]. Puma concolor samples lacking enFeLV were shown
to be more permissive to FeLV infection than domestic cat samples [63]. In addition,
enFeLV-LTR elements seem to negatively correlate with exogenous FeLV replication [63].
If target sequences for CRISPR/SaCas9 on the exogenous FeLV are identical to enFeLV
sequences, enFeLV also becomes a target. This effect on the enFeLV copy numbers might
have implications not yet fully realized. In the present in vitro study, only Target 7 had
100% identity with enFeLV sequences.
Overall, twelve target sites, distributed within the FeLV provirus, were compared for
their rates of DNA editing by CRISPR/SaCas9 using transfection. The highest efficacy in
indel creation was found in the targets localized in the gag and pol (Targets 4, 5, 6, and
8). Thus, in a follow-up experiment, five targets, including the four mentioned above,
resulting in highest indel production and the most promising target site in the env, T10,
were further investigated in a transduction study. Again, the highest indel efficiency was
found in regions targeting the gag and pol.
In addition to the anticipated specific editing of target sites, undesired off-target
nucleotide changes often represent obstacles for successful applications. In treatments,
such as the targeting of the FeLV provirus, in particular, which is integrated in the genome
all over the organism, off-site targeting needs to be investigated closely. Investigations of
SaCas9, the enzyme used in the present study, revealed double-strand breaks at a subset of
off-target sites, previously identified for the widely applied SpCas9, with significantly lower
read counts [69]. In addition, recent publications have described new editing approaches,
with improved specificity of base editors [70,71]. Thus, potential future steps towards
in vivo experiments should closely investigate these risks, in order to find a safe treatment
option.
DNA editing could be shown by T7E1 and TIDE, at all chosen target sites, with the
highest % NHEJ in the highly conserved gag and pol regions. Five promising candidates
were further investigated during a transduction experiment, where AAV-DJ gene therapy
vectors were designed, containing the CRISPR/SaCas9, as well as the target information.
Again, successful gene editing was confirmed by T7E1 and TIDE analyses. FeLV p27 antigen
was quantified, in order to determine the effect of these indels. A significant reduction in
all three cell lines, for the two gene therapy vectors vT4 and vT5, both targeting the FeLV
gag, was found. While Target 5 is localized in the p27 core protein, Target 4 and Target 6 are
both localized in p15.
However, a significant provirus reduction using qPCR, targeting either env or gag,
could only be shown for Target 8 in CRFK cells (Supplementary Figure S1 and data not
shown, respectively). It needs to be mentioned that primers and probes of both qPCR assays
did not cover any of the specific target sites. An earlier study by Chakrabarti et al. showed
that the most common CRISPR/Cas9 indel mutations are 1 bp insertions or deletions
(with 44% and 26%, respectively), leading to frameshifts [72]. Thus, this indicates that
the FeLV provirus sequence is likely still present in the genome. A reduction of provirus,
by qPCR quantification, might not have been observed, even if nearby sequences were
mutated, leading to provirus numbers in the same range as our controls. In addition, some
cells might not be transduced by AAV, thus still producing intact provirus and continuing
with the production of infectious FeLV, resulting in a dynamic process. In addition, all
measurements were performed on day 3; perhaps a more pronounced effect could have
been seen at a later time point. It would be highly interesting to analyze induced mutations
and viral progenies. Studying their infectivity efficiency and tropism should be investigated
in a follow-up study.
Differences between the targeted and the original provirus might only lay in their
ability to produce intact antigens, which are necessary to produce infectious virus particles.
Insertions or deletions of 1–2 bp can lead to frameshifts, which might impair the entire
infection cycle. Experiments in all three cell lines clearly showed the successful applicability
of CRISPR/SaCas9-mediated gene editing leading to a reduction of FeLV p27 antigen levels.
Thus far, only single targets have been investigated. However, combinations of multiple
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targets might even provide better results. Thus, future studies should not only include the
most promising candidates in the gag and pol regions, but also include targets in the LTR. A
combination of targets further apart might increase the chances for excision between two
different sgRNAs and, thus, result in the loss of a bigger FeLV region. Studies using SpCas9
with multiplex sgRNAs in vitro, as well as in vivo (mouse model), to excise HIV-1 provirus
showed great promise, not only in enhancing cleavage efficiency but also in preventing
potential HIV escape, due to its high mutation rate [73].
Several established methods provide the means to determine the extent and effi-
ciency of CRISPR/SaCas9-induced gene editing. High-throughput sequencing, with next-
generation sequencing (NGS) as a gold standard, can analyze an entire mutation spectrum.
Despite high error rates in GC- and AT-rich regions and homopolymer stretches, in general,
its error rate is low at <0.4% [74] and improving constantly with newly developed NGS
platforms. By producing a huge amount of information and, alongside this, the need for
sophisticated data analysis, the costs remain significant, despite recent reductions. Alterna-
tive methods have evolved, which provide a simpler and cheaper approach to measure the
efficiency and extent of genome editing events.
T7E1 is a structure-selective enzyme that is widely used to detect DNA mismatches. Its
straight-forward and cost-effective approach provides semi-quantitative information on the
presence of heteroduplexes representing nucleotide mismatches, as a result of NHEJ [50].
Although this method provides information about the amount of mutated sequences, their
nature and diversity remain unknown.
Alternatively, the TIDE algorithm is a fast and cost-effective approach, accurately
quantifying the editing efficacy and predominant types of indels [52]. By analyzing and
comparing Sanger sequence traces, generated from convoluted WT and edited samples,
the TIDE software identifies and quantifies induced mutations. Indel estimates with TIDE
have been shown to be typically congruent with those from NGS; however, the sensitivity
of TIDE can only identify indels up to about 1–2% [51].
Apart from NGS, T7E1, and TIDE, other site-specific nuclease validation systems
also exist, such as the Indel Detection by Amplicon Analysis (IDAA) assay [75]. This fast,
sensitive, and simple method is based on tri-primer amplicon labelling and DNA capillary
electrophoresis detection. Comparisons of TIDE and IDAA revealed similar indel frequency
results; however, their numbers were about 10–20% lower than targeted NGS [51]. Previous
studies showed that using the NGS approach for assessing editing efficiencies in cell pools
can accurately portray editing events [51]. Compared to TIDE and T7E1, NGS seems to be
more reliable and robust over a broad spectrum of indel sizes; however, due to its labor-
and cost-intensive features, it is not always feasible to use this method.
Due to cost effectiveness, as well as efficiency, the CRISPR/SaCas9 target sites, in-
vestigated in the present study, were analyzed by T7E1 assay and compared to the TIDE
algorithm output. When comparing the data obtained by T7E1, measured on a FA or
by gel and TIDE, a significant correlation was found. However, although general trends,
such as the most efficiently cleaved target, were consistent in the different techniques,
the specific % NHEJ events were not. The reasons for this are manifold and can partially
be explained by how the different assays work. T7E1 is an endonuclease, which cleaves
wherever mismatches in the DNA causes heteroduplexes to form. It easily detects indel
variants; however, single nucleotide polymorphisms are poorly recognized [52,76]. Thus,
samples with greater indel size heterogeneity, based on TIDE analysis, more closely reflect
the overall editing efficiency by T7E1. In addition, a prerequisite for this technique is the
presence of different sequences, resulting in a plateau, which has been described at around
40–50% [51,76]. The results found in our study might suffer from such a plateau situation,
in some cases. Thus, even with very high NHEJ, a low and limited detection range is
expected, which might be even more pronounced, in the case of a very narrow mutation
range. Depending on the method of evaluation, another bias needs to be addressed. The
choosing of the band area, within an agarose gel after T7E1 digestion, might influence the
final measurements of NHEJ. In order to provide a second evaluation of the efficiency of
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T7E1 digestion, this experiment was also analyzed on a FA. In addition, T7E1 and TIDE
are both methods which are PCR-based and, therefore, have additional limitations. These
include, but are not limited to, not being able to detect large mutations, which tamper
with the binding sites of the primers, as well as the possibility of a bias for smaller ampli-
cons. Despite all these limiting features, a general trend was obvious pointing towards the
highest % NHEJ in the highly conserved gag and pol regions. In addition, TIDE analysis
revealed higher amounts of deletions, compared to insertions for all the sites investigated
during transduction.
Cats infected with FeLV can undergo various outcomes. Among them, viremic sick
cats showed the highest FeLV provirus and viral loads, whereas regressively infected cats
showed significantly lower levels [13]. Unlike HIV and the feline immunodeficiency virus
(FIV; the lentivirus of the cat), where the virus resides mainly in peripheral CD4+ T cells,
FeLV has been found in a broad variety of cell types. However, viral RNA and provirus
loads vary significantly between different tissues, with the highest loads in viremic sick
cats in the lymphoid tissues, intestinal tract, and salivary glands [13]. Provirus tissue
loads were found to reach levels of several copies per cell [13], clearly stating that any
attempt targeting this provirus also needs to access all these different cell types. Although
AAV-DJ was clearly superior in infecting different feline cell lines in vitro, when compared
to wild-type AAV serotypes, AAV-DJ/8, and Anc80L65, in vivo experiments using AAV-DJ
will be necessary to corroborate these results. Thus, if no gene therapy vector can be found
infecting most tissues in vivo, studies might need be directed to the three main areas of
FeLV infection: the lymphoid tissues, the intestinal tract, and the salivary glands. It will
be interesting to see whether this system, thus far successfully applied in vitro, will also
succeed in vivo.
Previous studies using CRISPR editing in FIV-infected feline T lymphocyte cell lines
discussed the possibility of overwhelming the functionality of the gene editing method by
using an acute FIV infection strategy versus targeting latently infected cells [77]. The latent
reservoir in peripheral CD4+T cells, during the asymptomatic phase of FIV-C infection, was
found to be approximately one in 103 cells, of which only one in 102 was also replication
competent, resulting in an overall infection rate of around one in 105 cells [78]. Thus,
it was stated that the lentiviral gene editing strategy might be more effective in latently
FIV-infected cats [77]. Due to the biology of FeLV infection and the different outcomes,
that depend on the balance of the virus and the immune system of the cat [79], we hypoth-
esize that even incomplete provirus destruction, accompanied with a reduction of viral
replication, might provide the immune system with the means to overcome progressive
infection and enable the cat to reach a regressive infection outcome. Since such a change in
FeLV infection outcome results in significant differences of the cat’s survival expectancy,
as well as non-infectivity to co-housed cats, a regressive infection outcome would already
be highly desirable. Of course, complete elimination of the FeLV provirus would be even
more attractive, but its achievability remains unclear.
Consistent with our aim to cure cats from progressive FeLV infection, and while our
experiments were underway, CRISPR/Cas9 strategies have also been applied in various
studies, with the goal of achieving a permanent cure for HIV/AIDS. Thus, the SpCas9
system has been successfully applied in the disruption or excision of HIV itself, as well as
its co-receptors CCR5 and CXCR4 [80–83]. Enhanced HIV-1 excision in cultured cells could
be obtained by a combination of sgRNAs targeting LTRs and the viral structural genes in
the SpCas9 system [84]. A proof-of-concept study demonstrated, also in vivo, excision of
HIV-1 DNA by CRISPR/SaCas9 upon delivery, by tail vain infection of transgenic mice
or retro-orbital inoculation in transgenic rats, using an AAV9 gene therapy vector [85].
Thus, future studies using SaCas9 to target FeLV provirus might benefit from some of the
experience gained in the HIV studies. Nonetheless, some differences exist between FeLV
and HIV that will make the combat against FeLV more challenging, such as the broad tissue
tropisms of FeLV. In contrast, the natural ability of cats to overcome viremia might come in
helpful. If we are able to destroy even only a part of the provirus, this might be sufficient to
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lower the virus burden to a level where the cat’s immune system can play an active role and
gain control over the virus. Therefore, complementary strategies, such as boosting innate
immunity using oligonucleotide-mediated immune system stimulation, should also be
considered when targeting the FeLV provirus [86]. Furthermore, FeLV is rather conserved
genetically; in contrast to HIV, it barely mutates. Whereas cases of mutant escapes have
been described in HIV; such sequence changes were seldomly found in cats [58]. Ultimately,
a lot of evidence points towards a successful application of SaCas9 in the fight against
progressive FeLV infection.
5. Conclusions
Curative treatments of many infectious diseases are nonexistent. Thus, new strategies,
such as the CRISPR/Cas9 system, need to be explored. Retroviral infections are generally
difficult to cure, since the provirus hides integrated within the host’s genome. Provirus
destruction does not only depend on highly specific targeting but also on the optimal
delivery of bioreactive molecules. To achieve this goal, AAVs, as gene delivery vectors,
have been investigated in vitro. The obtained information on tropism, and the efficiency of
infection within feline tissues, will be beneficial for future research with a focus on gene
therapy.
The present study focused on the application of the CRISPR/SaCas9 gene editing tool
in targeting FeLV-infected feline cell lines. Efficient provirus cleavage could be observed
first in transfection and afterwards in transduction experiments, with the highest indel
efficiency in the gag and pol region of FeLV. This study shows a proof of principle in the
application of CRISPR/SaCas9-mediated gene editing targeting FeLV provirus in vitro. The
levels of gene editing are highly encouraging, and therefore, this study is a good starting
point, and an important basis, for future in vivo experiments in cats infected with FeLV.
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Appendix A
Figure A1. Schematic representation and concentration of the AAV vectors used in this study. (A). AAV vectors used for the
determination of the tropism. (B). Gene therapy vectors.
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Figure A2. Fluorescent microscopy images of cells infected with 12 AAV serotypes. (A) FEA, (B) PG-4, (C) AK-D, (D) MT,
(E) Fc3Tg, (F) Fcwf-4, (G) Fet-J, and (H) HEK cells infected with 12 AAV serotypes. Infection of nine natural AAV serotypes
(AAV1-9), two AAV hybrid strains (AAV-DJ and AAV-DJ/8), and Anc80L65, all EGFP tagged from the upper left to the
lower right, using a multiplicity of infection (MOI) between 100 and 100,000 (specific MOI depended on the cell line) after
3 days. Red squares mark the minimal MOI at which a significant AAV infection could be visualized for each AAV serotype
by fluorescence (corresponding to ≥50% infection); red dashed squares represent the minimal MOI, at which a EGFP signal
was clearly visible, but not reaching 50% infection. The bars represent 400 µm.
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Figure A3. SaCas9 cleavage efficiency in three cell lines determined by T7E1, visualized on an agarose gel. T7E1 assay
showing percentage of NHEJ at the 12 FeLV target sites after transfection of CRFK, FEA, and PG-4 cells and sorting (A).
Selected results showing SaCas9 cleavage efficiency at the Target 5 in CRFK, PG-4, and FEA cells (B) and Targets 6–12 in
PG-4 cells (C) visualized after T7E1 cleavage on agarose gels. Red triangles indicate cleaved fragments.





Figure A4. Comparison of CRISPR/SaCas9 activity leading to indels after transduction. After CRISPR/SaCas9 transduction
using the AAV-DJ vectors vT4 (Target 4, vKHH1), vT5 (Target 5, vKHH3), vT6 (Target 6, vKHH4), vT8 (Target 8, vKHH2),
and vT10 (Target 10, vKHH5), frequency of indels (%) were compared using TIDE (A,D,G) and the T7E1 assays. T7E1
efficiency was determined by parallel capillary electrophoresis using a fragment analyzer (FA, graphs (B,E,H)) and band
intensity comparison on an agarose gel (C,F,I). Transductions were performed on CRFK (A–C), FEA (D–F), and PG-4 cells
(G–I). Frequency of indels (%) was tested for significant differences by Kruskal–Wallis, one-way ANOVA by ranks (pKW as
indicated), and subsequently by Dunn’s post-test: * = p < 0.05. The data are shown as scatter dot plots. The horizontal line
represents the mean with SD.
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Figure A5. Comparison of CRISPR/SaCas9 activity between cell lines. After CRISPR/SaCas9 transduction using the
AAV-DJ vectors, the frequency of indels (%) was compared between the cell lines. Each raw corresponds to one Target:
graphs (A–C) to Target 4 (vKHH1); (D–F) to Target 5 (vKHH3); (G–I) to Target 6 (vKHH4); (J–L) to Target 8 (vKHH2); and
(M–O) to Target 10 (vKHH5). The graphs (A,D,G,J,M) represent results determined by TIDE; (B,E,H,K,N) by T7E1 using
the fragment analyzer (FA); (C,F,I,L,O) by T7E1 quantifying signal intensity on a gel. Frequency of indels (%) was tested
for significant differences by Kruskal–Wallis, one-way ANOVA by ranks (pKW as indicated), and subsequently by Dunn’s
post-test: * = p < 0.05. The data are shown as scatter dot plots. The horizontal line represents the mean with SD.
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